Ephedrine sulfate injection - Nexus Pharmaceuticals
Alternative Names: Emerphed; Ephedrine sulfate - Nexus PharmaceuticalsLatest Information Update: 03 Mar 2023
At a glance
- Originator Nexus Pharmaceuticals
- Class Analgesics; Antihypotensives; Decongestants; Propanolamines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Alpha 1 adrenergic receptor agonists; Beta adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypotension
Most Recent Events
- 01 Mar 2023 Nexus Pharmaceuticals has several additional worldwide patents approved for its ephedrine sulfate injection line of vials and syringes
- 01 Mar 2023 US FDA approves ephedrine sulfate injection as pre-filled syringes for Hypotension in USA
- 17 Aug 2021 Nexus Pharmaceuticals has patent protection for the applications of ready-to-use ephedrine sulfate injection in USA